Pioglitazone for diabetes prevention in impaired glucose tolerance

New England Journal of Medicine

Volumn 364, Issue 12, 2011, Pages 1104-1115

  DeFronzo, Ralph A ^a   Tripathy, Devjit ^a   Schwenke, Dawn C ^c,d   Banerji, MaryAnn ^e   Bray, George A ^f   Buchanan, Thomas A ^g   Clement, Stephen C ^h   Henry, Robert R ⁱ   Hodis, Howard N ^g   Kitabchi, Abbas E ^j   Mack, Wendy J ^g   Mudaliar, Sunder ⁱ   Ratner, Robert E ^k   Williams, Ken ^b   Stentz, Frankie B ^j   Musi, Nicolas ^a   Reaven, Peter D ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b KenAnCo Biostatistics   (United States)

^c Phoenix Veterans Affairs Health Care System   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k MEDSTAR RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; EDEMA; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMMUNOPATHOLOGY; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UROGENITAL TRACT DISEASE; WEIGHT GAIN;

EID: 79953232077     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1010949     Document Type: Article

References (40)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8.
2. Diabetes programme: facts and figures. Geneva: World Health Organization, 2007. (http://www.who.int/diabetes/facts/en.)
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
4. DeFronzo RA. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2005;353:2643-53. (Pubitemid 41817713)
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
8. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic betacell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22. (Pubitemid 43343284)
9. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [Erratum, Lancet 2006;368:1770.]
10. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6. (Pubitemid 40446330)
11. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803. (Pubitemid 34970933)
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7. (Pubitemid 34680970)
13. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248.e5-256.e5.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-7. [Erratum, N Engl J Med 2007;357:100.]
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31:Suppl:S55-S60.
16. DeFronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 2009;9:17.
17. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10. (Pubitemid 27143390)
18. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9. (Pubitemid 28090756)
19. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53. (Pubitemid 33131615)
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70. (Pubitemid 29418240)
21. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67. (Pubitemid 12194400)
22. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55:1430-5. (Pubitemid 44195383)
23. Kalbfleisch J, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
24. Lachin JM, Wei LJ. Estimators and tests in the analysis of multiple nonindependent 2 x 2 tables with partially missing observations. Biometrics 1988;44:513-28. [Erratum, Biometrics 1988;44:923.]
25. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500. (Pubitemid 40116699)
26. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871-E883. (Pubitemid 46411067)
27. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10. (Pubitemid 36042113)
28. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137-44.
29. Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care 2009;32:2027-32.
30. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464-9.
31. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
32. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-9. (Pubitemid 351697954)
33. Knowler WC, Fowler SE, Hamman RF, et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86. [Erratum, Lancet 2009;374:2054.]
34. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9. (Pubitemid 46048554)
35. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9. (Pubitemid 32888853)
36. Miyazaki Y, De Filippis E, Bajaj M, et al. Predictors of improved glycemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. Br J Diabetes Vasc Dis 2005;5:28-35. (Pubitemid 40352807)
37. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
38. Crouse JR III. Thematic review series: patient-oriented research - imaging atherosclerosis: state of the art. J Lipid Res 2006;47:1677-99.
39. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73. (Pubitemid 351482795)
40. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81. (Pubitemid 44903861)